BS Summary: This article contains 17 faulty reasoning types, including Optimism Bias, Post Hoc (False Cause), and Ambiguity (Equivocation), with Framing Effect as the most egregious example at 62.5% saturation with 70 hits. Analysis detected 526 faulty-reasoning hits from 112 analyzed words, generating a BS Score of 73.2% and a BS Rank of 82% (3,989 of 21,166 articles). This article is worse (more manipulative) than 81.20% of the article peer group.
US drug regulators signed off on a new pill designed to lower cholesterol levels far beyond what traditional statins can achieve.
Merck’s Lipfendra achieved similar results to injectable treatments, potentially heralding a new era of easier prevention for people wanting to bring down artery-clogging cholesterol.
“This is a game changer,” one cardiologist said, adding that many patients were hesitant to go on the injection treatment.
Heart disease is the leading cause of death in the US, so a more powerful and accessible option could help more people manage the risk.
Merck could soon have competition in the field: AstraZeneca is also working on a cholesterol pill.
Speakers
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.